ERBB2 and breast cancer: Across the four BC subgroups, the HR( +)/HER2( +) group had the highest OS at 22.05 months (18.73–24.67) compared to the lowest in the HR(−)/HER2(−) at 5.62 months (5.19–6.18) (log rank test, p < 0.0001).